MedTrace Logo

BOTOX® in the Treatment of Crow's Feet Lines in Japan

NCT01797081 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-04-16

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthus Rhytides).

Conditions

  • Lateral Canthus Rhytides
  • Crow's Feet Lines

Interventions

BIOLOGICAL

botulinum toxin Type A (24 U)

24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.

BIOLOGICAL

botulinum toxin Type A (12 U)

12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.

OTHER

Normal Saline

Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-07-18
Completion
2014-07-07

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01797081 on ClinicalTrials.gov